Atara Biotherapeutics, Inc. (ATRA)
8.59
-0.84
(-8.91%)
USD |
NASDAQ |
Oct 23, 16:00
8.64
+0.05
(+0.58%)
After-Hours: 20:00
Atara Biotherapeutics Enterprise Value : 122.66M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 122.66M |
| October 22, 2026 | 130.59M |
| October 21, 2026 | 129.84M |
| October 20, 2026 | 128.04M |
| October 19, 2026 | 126.15M |
| October 16, 2026 | 128.23M |
| October 15, 2026 | 132.67M |
| October 14, 2026 | 131.82M |
| October 13, 2026 | 129.41M |
| October 12, 2026 | 130.12M |
| October 09, 2026 | 131.06M |
| October 08, 2026 | 128.70M |
| October 07, 2026 | 130.02M |
| October 06, 2026 | 133.61M |
| October 05, 2026 | 130.31M |
| October 02, 2026 | 131.06M |
| October 01, 2026 | 121.43M |
| September 30, 2026 | 121.81M |
| September 29, 2026 | 117.56M |
| September 28, 2026 | 120.58M |
| September 25, 2026 | 124.74M |
| September 24, 2026 | 122.19M |
| September 23, 2026 | 122.38M |
| September 22, 2026 | 125.87M |
| September 21, 2026 | 130.12M |
| Date | Value |
|---|---|
| September 18, 2026 | 133.05M |
| September 17, 2026 | 133.24M |
| September 16, 2026 | 137.01M |
| September 15, 2026 | 130.69M |
| September 14, 2026 | 128.89M |
| September 11, 2026 | 130.12M |
| September 10, 2026 | 134.94M |
| September 09, 2026 | 135.12M |
| September 08, 2026 | 138.15M |
| September 04, 2026 | 133.71M |
| September 03, 2026 | 131.54M |
| September 02, 2026 | 130.69M |
| September 01, 2026 | 126.72M |
| August 31, 2026 | 125.59M |
| August 28, 2026 | 128.42M |
| August 27, 2026 | 128.89M |
| August 26, 2026 | 130.12M |
| August 25, 2026 | 134.46M |
| August 24, 2026 | 130.87M |
| August 21, 2026 | 133.14M |
| August 20, 2026 | 130.12M |
| August 19, 2026 | 132.20M |
| August 18, 2026 | 123.89M |
| August 17, 2026 | 120.49M |
| August 14, 2026 | 117.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.834M |
| Revenue (Quarterly) | 0.63M |
| Total Expenses (Quarterly) | 5.464M |
| EPS Diluted (Quarterly) | -0.3216 |
| Gross Profit Margin (Quarterly) | 69.68% |
| Profit Margin (Quarterly) | -767.3% |
| Earnings Yield | -16.28% |
| Normalized Earnings Yield | -14.46 |